UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of November 2022
Commission file number: 001-38041
SCISPARC LTD.
(Translation of registrant’s name into English)
20 Raul Wallenberg Street, Tower A,
Tel Aviv 6971916 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):
CONTENTS
On October 28, 2022, SciSparc
Ltd. (the “Company”) issued a press release entitled “SciSparc: Wellution™
Successfully Launched a New Keto Gummies Apple Cider Vinegar Product and Generated $100,000 In Revenues Within 30 Days”.
A copy of this press release is furnished herewith as Exhibit 99.1 and incorporated by reference herein.
On November 1, 2022, the Company
issued a press release entitled “SciSparc: Wellution™ Signs an Agreement with Logistics Facilities in New Jersey
to Supports its Expansion to Additional e-Commerce Platforms”. A copy of this press release is furnished herewith as Exhibit 99.2
and incorporated by reference herein.
The first and second paragraphs
and the section entitled “Forward-Looking Statements” of Exhibit 99.1 and the first and second paragraphs and the section entitled “Forward-Looking
Statements” of Exhibit 99.2 to this Report of Foreign Private Issuer on Form 6-K
are incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-266047, File No. 333-233417
and File No. 333-248670) and on Form S-8 (File No. 333-225773) filed with the Securities and Exchange Commission to be a part
thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
SciSparc Ltd. |
| |
|
|
| Date: November 1, 2022 |
By: |
/s/ Oz Adler |
| |
|
Name: |
Oz Adler |
| |
|
Title: |
Chief Executive Officer & Chief Financial Officer |
3
Exhibit 99.1
SciSparc:
Wellution™ Successfully Launched a New Keto Gummies Apple Cider Vinegar Product and Generated $100,000 In Revenues Within 30 Days
Since
launch the new product has had approximately 117% ROI
TEL
AVIV, Israel, Oct. 28, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty
clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today
announced that SciSparc Nutraceuticals Inc., its wholly owned subsidiary, has successfully launched a new keto gummies apple cider
vinegar product under its brand Wellution™ on Amazon.com.
In
the 30 days following the launch, the new product has generated more than $100,000 in revenues with an ROI (return on investment after
costs of goods, marketing, advertising, shipping, storage and commissions) to the Company of approximately 117%.
“Our
expansion plans for the WellutionTM brand include launching new products that will appeal to current and future customers.
In the first 30 days since its launch, this new product has achieved impressive results and we are pleased with its success so far,”
Oz Adler, SciSparc’s Chief Executive Officer, commented. “To continue expanding the Wellution’s reach, we intend to develop
new attractive products, either independently or in collaboration with third parties, while reducing production and supply chain costs
and exploring new markets and sales channels.”
View
the product at: https://www.amazon.com/Keto-Gummies-Apple-Cider-Vinegar/dp/B0B4ST8TZQ?ref_=ast_sto_dp
About
SciSparc Ltd. (NASDAQ: SPRC):
SciSparc
Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s
focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the
Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110
for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; and
SCI-210 for the treatment of autism spectrum disorder and status epilepticus.
SciSparc
also owns Wellution™, a brand that sells dozens of hemp-based products, including hemp gummies, hemp oil capsules, hemp gel, hemp
cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are
all manufactured in the United States. Wellution™ offers eight variations of natural hemp candy supplements under two parent Amazon
Standard Identification Numbers (“ASINs”) on Amazon that are differentiated by their hemp oil potency. The leading parent
ASIN, which was launched in 2019, has received over 26,500 reviews and is consistently ranked as the #1 best seller in the category.
In total, the brand has over 40,000 product reviews, most of which are 4 and 5-star reviews.
Forward-Looking
Statements:
This
press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses
its expansion plans for the Wellution brand, developing and launching new products, its intention to reduce production and supply chain
costs and the exploration of new markets and sales channels. Because such statements deal with future events and are based on SciSparc’s
current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc
could differ materially from those described in or implied by the statements in this press release. The forward- looking statements contained
or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk
Factors” in SciSparc’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”)
on April 28, 2022, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation
to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information,
future events or circumstances or otherwise.
Investor
Contact:
IR@scisparc.com
Tel: +972-3-6167055
Exhibit 99.2
SciSparc: Wellution™ Signs an Agreement
with Logistics Facilities in New Jersey to Supports its Expansion to Additional e-Commerce Platforms
Agreement
is expected to optimize handling and shipment processes and reduce direct sales costs
TEL AVIV, Israel, Nov. 01, 2022
(GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage
pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that
SciSparc Nutraceuticals Inc. ("SciSparc Nutraceuticals"), its wholly owned subsidiary, has signed an agreement with logistics
facilities in New Jersey, U.S. as part of SciSparc Nutraceuticals' plans to expand sales of its WellutionTM ("the
brand") products to new online platforms.
The logistics facilities are
located near the second largest port in the U.S., Newark Airport and JFK Airport in New York. The logistics facilities offer an aggregate
of 100,000 square feet with 20 loading docks for loading and unloading container and trucks. The facilities handle supply chain, inventory
and order processing for many e-Commerce businesses.
"The success of an online
brand depends, amongst other things, on operational efficiency and low costs that enable high margins on each sale. The establishment
of access to advanced logistics infrastructure, to support our shift from selling our products on Amazon to making direct sales and expanding
to additional eCommerce platform , is a key element in our plans for the future," Oz Adler, SciSparc's Chief Executive Officer,
commented. "The facilities we engaged with offer a wide range of services - from intake and storage space for WellutionTM products,
order processing direct shipping to the brand's customers and more. We intend to commence preparations for the launch of our direct
sales operations and we explore possible platforms to launch in the brand’s products".
About SciSparc Ltd. (NASDAQ:
SPRC):
SciSparc Ltd. is a specialty
clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating
and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently
engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment
of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the
treatment of autism spectrum disorder and status epilepticus.
About SciSparc Nutraceuticals
Inc.
SciSparc owns Wellution™,
a brand that sells dozens of hemp-based products, including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height
pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United
States. Wellution™ offers eight variations of natural hemp candy supplements under two parent Amazon Standard Identification Numbers
(“ASINs”) on Amazon that are differentiated by their hemp oil potency. The leading parent ASIN, which was launched in 2019,
has received over 26,500 reviews and is consistently ranked as the #1 best seller in the category. In total, the brand has over 40,000
product reviews, most of which are 4 and 5-star reviews.
Forward-Looking Statements:
This press release contains forward-looking
statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and
other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses its expansion plans for the
WellutionTM brand and its future success, preparing to launch direct sales operations and exploring other platforms to launch in the
brand’s products, its intention to reduce supply chain and direct sales costs. Because such statements deal with future events
and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance
or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-
looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed
under the heading “Risk Factors” in SciSparc's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission
(the “SEC”) on April 28, 2022, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims
any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether
as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055